Kontakt

Eurobio Onkologie

EndoPredict: Case studies

Prof. Dr. med. Michael Untch, Head of Clinic for Gynecology, Gynecologic Oncology and Obstetrics, Head of Breast Interdisciplinary Cancer Center Department of Obstetrics and Gynecology, HELIOS Clinic Berlin-Buch in Berlin, Germany

Watch Prof. Untch’s Case Study

  • 43 years old, premenopausal, pT1c, N0, G2, L0, V0, R0, ER 100%, HER2-, PR 100%, Ki67 15%, early-stage breast cancer patient
  • Poll of other clinicians’ case opinions
  • How her EndoPredict result supported a confident treatment decision
  • Clinical validation of the test in this patient group
Watch Now

Get Clear Results

Based on her individualized risk score. See her full report

0 %

Risk of distant recurrence within 10 years

0 %

Absolute individualized chemotherapy benefit

0 %

5–15 year late distant recurrence risk*

*with 5 years of endocrine therapy alone

Full Report

Have Informed Conversations

EndoPredict results are simple to understand and straightforward to explain.

For this case, you could say:

  • Your EndoPredict result indicates that your cancer is unlikely to come back in other parts of your body.
  • This result takes into account both your tumor’s gene activity and clinical information, giving a personalized view of your situation.
  • It suggests there is a 92% probability that your cancer will not return within the next 10 years.
  • Chemotherapy could slightly improve this probability by about 2%, but for many patients, the small benefit may not justify the potential side effects.

Make Confident Decisions Knowing Her Result

  • Comes from the most advanced, second-generation prognostic and predictive test1,2
  • Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
  • Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
  • Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
  • Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11

What it Meant for this Patient

Her report breakdown

Based on her clear EndoPredict result, the patient and her clinician decided to proceed without chemotherapy – avoiding unnecessary side effects while feeling confident in her favorable long-term outlook.

  1. Sestak I. et al.: Vergleich der Leistungsfähigkeit von 6 prognostischen Signaturen für Östrogenrezeptor-positiven Brustkrebs. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
  2. Sestak I. et al.: Vorhersage des Nutzens einer Chemotherapie durch EndoPredict bei Patientinnen mit Brustkrebs, die eine adjuvante endokrine Therapie plus Chemotherapie oder nur eine endokrine Therapie erhalten haben. Breast Cancer Res Treat. 2019
  3. Filipits M. et al.: Ein neuer molekularer Prädiktor für Fernrezidive bei ER-positivem, HER2-negativem Brustkrebs ergänzt herkömmliche klinische Risikofaktoren um unabhängige Informationen. Clin. Cancer Res. 2011
  4. Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
  5. Filipits M. et al.: Vorhersage des Fernrezidivs mittels EndoPredict bei Frauen mit ER+, HER2-, nodalpositivem und nodalnegativem Brustkrebs, die nur mit endokriner Therapie behandelt wurden. Clin Cancer Res. 2019
  6. Constantinidou A. et al.: Klinische Validierung von EndoPredict bei prämenopausalen Frauen mit ER-positivem, HER2-negativem primärem Brustkrebs. Clin. Cancer Res. 2022
  7. Buus R. et al.: Comparison of EndoPredict and EPclin with Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
  8. Klein, E. et al.: Langzeitergebnisse unter Verwendung von EndoPredict als Biomarker für die Risikostratifizierung und Chemotherapieentscheidung bei hormonrezeptorpositivem, HER2-negativem Brustkrebs im Frühstadium. Breast Cancer Res Treat. 2024
  9. Schmitt, W. D. et al: Retrospektive Auswertung der Ergebnisse in einer realen, prospektiven Kohorte mit EndoPredict: Ergebnisse aus dem Charité-Register. SABCS 2022
  10. Vázquez-Juarez D. et al.: Follow-up einer prospektiven Kohorte mexikanischer prämenopausaler Frauen mit Brustkrebs, die eine geführte adjuvante Behandlung mit dem EndoPredict-Assay erhielten. SABCS 2021
  11. Loibl S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
Prof. Dr. med. Michael Untch, Head of Clinic for Gynecology, Gynecologic Oncology and Obstetrics, Head of Breast Interdisciplinary Cancer Center Department of Obstetrics and Gynecology, HELIOS Clinic Berlin-Buch in Berlin, Germany

Watch Prof. Untch’s Case Study

  • 50 years old, postmenopausal, pT2, N1, G2, L0, V0, R0, ER 30/80%, PR 100/90%, Ki67 10%, lobular early-stage breast cancer patient
  • Poll of other clinicians’ case opinions
  • How her EndoPredict result changed the treatment decision
  • Clinical validation of the test in this patient group
Watch Now

Get Clear Results

Based on her individualized risk score. See her full report

0 %

Risk of distant recurrence within 10 years

0 %

Absolute individualized chemotherapy benefit

0 %

5–15 year late distant recurrence risk*

*with 5 years of endocrine therapy alone

Full Report

Have Informed Conversations

EndoPredict results are simple to understand and straightforward to explain.

For this case, you could say:

  • Your EndoPredict result shows that your cancer is at low-risk of coming back in other parts of your body.
  • The result combines information from your tumor’s gene activity and clinical factors to give a clear picture of your situation.
  • Based on this, there is a 91% chance your cancer will not return within 10 years.
  • Adding chemotherapy could increase this chance by 3%, but the small potential benefit may not outweigh the possible side effects.

Make Confident Decisions Knowing Her Result

  • Comes from the most advanced, second-generation prognostic and predictive test.1,2
  • Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
  • Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
  • Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
  • Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11

What it Meant for this Patient

Guided by her result, the patient and her clinician chose to continue treatment without chemotherapy, sparing her from potential side effects and giving them confidence in her treatment plan.

Her report breakdown
  1. Sestak I. et al.: Vergleich der Leistungsfähigkeit von 6 prognostischen Signaturen für Östrogenrezeptor-positiven Brustkrebs. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
  2. Sestak I. et al.: Vorhersage des Nutzens einer Chemotherapie durch EndoPredict bei Patientinnen mit Brustkrebs, die eine adjuvante endokrine Therapie plus Chemotherapie oder nur eine endokrine Therapie erhalten haben. Breast Cancer Res Treat. 2019
  3. Filipits M. et al.: Ein neuer molekularer Prädiktor für Fernrezidive bei ER-positivem, HER2-negativem Brustkrebs ergänzt herkömmliche klinische Risikofaktoren um unabhängige Informationen. Clin. Cancer Res. 2011
  4. Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
  5. Filipits M. et al.: Vorhersage des Fernrezidivs mittels EndoPredict bei Frauen mit ER+, HER2-, nodalpositivem und nodalnegativem Brustkrebs, die nur mit endokriner Therapie behandelt wurden. Clin Cancer Res. 2019
  6. Constantinidou A. et al.: Klinische Validierung von EndoPredict bei prämenopausalen Frauen mit ER-positivem, HER2-negativem primärem Brustkrebs. Clin. Cancer Res. 2022
  7. Buus R. et al.: Comparison of EndoPredict and EPclin with Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
  8. Klein, E. et al.: Langzeitergebnisse unter Verwendung von EndoPredict als Biomarker für die Risikostratifizierung und Chemotherapieentscheidung bei hormonrezeptorpositivem, HER2-negativem Brustkrebs im Frühstadium. Breast Cancer Res Treat. 2024
  9. Schmitt, W. D. et al: Retrospektive Auswertung der Ergebnisse in einer realen, prospektiven Kohorte mit EndoPredict: Ergebnisse aus dem Charité-Register. SABCS 2022
  10. Vázquez-Juarez D. et al.: Follow-up einer prospektiven Kohorte mexikanischer prämenopausaler Frauen mit Brustkrebs, die eine geführte adjuvante Behandlung mit dem EndoPredict-Assay erhielten. SABCS 2021
  11. Loibl S. et al.: Brustkrebs im Frühstadium: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
Prof. Dr. med. Michael Untch, Head of Clinic for Gynecology, Gynecologic Oncology and Obstetrics, Head of Breast Interdisciplinary Cancer Center Department of Obstetrics and Gynecology, HELIOS Clinic Berlin-Buch in Berlin, Germany

Watch Prof. Untch’s Case Study

  • 68 years old, pT1b (9 mm), N0, G2, L0, V0, PN0, R0, ER 100%, PR 15%, Ki67 40% early-stage breast cancer patient
  • Poll of other clinicians’ case opinions
  • How her EndoPredict result changed the treatment decision
  • Clinical validation of the test in this patient group
Watch Now

Get Clear results

Based on her individualized risk score. See her full report

0 %

Risk of distant recurrence within 10 years

0 %

Absolute individualized chemotherapy benefit

0 %

5–15 year late distant recurrence risk*

*with 5 years of endocrine therapy alone

Full Report

Have Informed Conversations

EndoPredict results are simple to understand and straightforward to explain.

For this case, you could say:

  • Your EndoPredict result shows a high-risk score.
  • This means that, based on your tumor’s genes and other clinical factors, there is a 19% chance your cancer could come back within 10 years - about 1 in 5 patients.
  • Chemotherapy can reduce this risk by around 8%, bringing it down to roughly 1 in 13, which may help improve your long-term outlook.

Make Confident Decisions Knowing Her Result

  • Comes from the most advanced, second-generation prognostic and predictive test.1,2
  • Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
  • Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
  • Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
  • Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11

What it Meant for this Patient

Based on her clear result, this patient and her clinician decided to add adjuvant chemotherapy to her treatment plan. They could make this choice with confidence knowing that although chemotherapy might be difficult, it will significantly lower her risk of recurrence.

Her report breakdown
  1. Sestak I. et al.: Vergleich der Leistungsfähigkeit von 6 prognostischen Signaturen für Östrogenrezeptor-positiven Brustkrebs. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
  2. Sestak I. et al.: Vorhersage des Nutzens einer Chemotherapie durch EndoPredict bei Patientinnen mit Brustkrebs, die eine adjuvante endokrine Therapie plus Chemotherapie oder nur eine endokrine Therapie erhalten haben. Breast Cancer Res Treat. 2019
  3. Filipits M. et al.: Ein neuer molekularer Prädiktor für Fernrezidive bei ER-positivem, HER2-negativem Brustkrebs ergänzt herkömmliche klinische Risikofaktoren um unabhängige Informationen. Clin. Cancer Res. 2011
  4. Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
  5. Filipits M. et al.: Vorhersage des Fernrezidivs mittels EndoPredict bei Frauen mit ER+, HER2-, nodalpositivem und nodalnegativem Brustkrebs, die nur mit endokriner Therapie behandelt wurden. Clin Cancer Res. 2019
  6. Constantinidou A. et al.: Klinische Validierung von EndoPredict bei prämenopausalen Frauen mit ER-positivem, HER2-negativem primärem Brustkrebs. Clin. Cancer Res. 2022
  7. Buus R. et al.: Comparison of EndoPredict and EPclin with Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
  8. Klein, E. et al.: Langzeitergebnisse unter Verwendung von EndoPredict als Biomarker für die Risikostratifizierung und Chemotherapieentscheidung bei hormonrezeptorpositivem, HER2-negativem Brustkrebs im Frühstadium. Breast Cancer Res Treat. 2024
  9. Schmitt, W. D. et al: Retrospektive Auswertung der Ergebnisse in einer realen, prospektiven Kohorte mit EndoPredict: Ergebnisse aus dem Charité-Register. SABCS 2022
  10. Vázquez-Juarez D. et al.: Follow-up einer prospektiven Kohorte mexikanischer prämenopausaler Frauen mit Brustkrebs, die eine geführte adjuvante Behandlung mit dem EndoPredict-Assay erhielten. SABCS 2021
  11. Loibl S. et al.: Brustkrebs im Frühstadium: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023

Suche

Nach oben scrollen